Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

This page shows the publications co-authored by Philip Kantoff and Eliezer Van Allen.
Connection Strength

1.145
  1. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019 Jul; 51(7):1194.
    View in: PubMed
    Score: 0.206
  2. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651.
    View in: PubMed
    Score: 0.189
  3. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8.
    View in: PubMed
    Score: 0.153
  4. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct; 4(10):1140-53.
    View in: PubMed
    Score: 0.146
  5. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8.
    View in: PubMed
    Score: 0.144
  6. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11428-11436.
    View in: PubMed
    Score: 0.051
  7. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 04; 375(5):443-53.
    View in: PubMed
    Score: 0.042
  8. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Jul 16; 162(2):454.
    View in: PubMed
    Score: 0.039
  9. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21; 161(5):1215-1228.
    View in: PubMed
    Score: 0.039
  10. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
    View in: PubMed
    Score: 0.036
  11. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53.
    View in: PubMed
    Score: 0.036
  12. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
    View in: PubMed
    Score: 0.033
  13. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20; 44(6):685-9.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.